These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 11642598)

  • 21. Intranasal immunization using biphasic lipid vesicles as delivery systems for OmlA bacterial protein antigen and CpG oligonucleotides adjuvant in a mouse model.
    Alcón VL; Baca-Estrada M; Vega-López MA; Willson P; Babiuk LA; Kumar P; Foldvari M
    J Pharm Pharmacol; 2005 Aug; 57(8):955-62. PubMed ID: 16102250
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and efficacy of nasal application of CpG oligodeoxynucleotide as a mucosal adjuvant.
    Kodama S; Abe N; Hirano T; Suzuki M
    Laryngoscope; 2006 Feb; 116(2):331-5. PubMed ID: 16467729
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transcutaneous immunization with a novel lipid-based adjuvant protects against Chlamydia genital and respiratory infections.
    Hickey DK; Aldwell FE; Beagley KW
    Vaccine; 2009 Oct; 27(44):6217-25. PubMed ID: 19698810
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intranasal immunization of mice with CpG DNA induces strong systemic and mucosal responses that are influenced by other mucosal adjuvants and antigen distribution.
    McCluskie MJ; Weeratna RD; Davis HL
    Mol Med; 2000 Oct; 6(10):867-77. PubMed ID: 11126201
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reduction of antigen expression from DNA vaccines by coadministered oligodeoxynucleotides.
    Weeratna R; Brazolot Millan CL; Krieg AM; Davis HL
    Antisense Nucleic Acid Drug Dev; 1998 Aug; 8(4):351-6. PubMed ID: 9743472
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CpG oligodeoxynucleotides as mucosal adjuvants.
    Iho S; Maeyama J; Suzuki F
    Hum Vaccin Immunother; 2015; 11(3):755-60. PubMed ID: 25751765
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent developments in mucosal immunomodulatory adjuvants.
    Harandi AM; Sanchez J; Eriksson K; Holmgren J
    Curr Opin Investig Drugs; 2003 Feb; 4(2):156-61. PubMed ID: 12669375
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Parameters of CpG oligodeoxynucleotide-induced protection against intravaginal HSV-2 challenge.
    Sajic D; Ashkar AA; Patrick AJ; McCluskie MJ; Davis HL; Levine KL; Holl R; Rosenthal KL
    J Med Virol; 2003 Dec; 71(4):561-8. PubMed ID: 14556270
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunostimulatory effects of plasmid DNA and synthetic oligodeoxynucleotides.
    Zelenay S; Elías F; Fló J
    Eur J Immunol; 2003 May; 33(5):1382-92. PubMed ID: 12731065
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CpG-ODN increases resistance of olive flounder (Paralichthys olivaceus) against Philasterides dicentrarchi (Ciliophora: Scuticociliatia) infection.
    Lee EH; Kim KH
    Fish Shellfish Immunol; 2009 Jan; 26(1):29-32. PubMed ID: 18992348
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lipid-based delivery of CpG oligonucleotides enhances immunotherapeutic efficacy.
    Wilson KD; de Jong SD; Tam YK
    Adv Drug Deliv Rev; 2009 Mar; 61(3):233-42. PubMed ID: 19232375
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Approaches to enhancing immune responses stimulated by CpG oligodeoxynucleotides.
    Mutwiri G; van Drunen Littel-van den Hurk S; Babiuk LA
    Adv Drug Deliv Rev; 2009 Mar; 61(3):226-32. PubMed ID: 19162103
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Strategies for enhancing the immunostimulatory effects of CpG oligodeoxynucleotides.
    Mutwiri GK; Nichani AK; Babiuk S; Babiuk LA
    J Control Release; 2004 May; 97(1):1-17. PubMed ID: 15147800
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased potency of BioThrax anthrax vaccine with the addition of the C-class CpG oligonucleotide adjuvant CPG 10109.
    Gu M; Hine PM; James Jackson W; Giri L; Nabors GS
    Vaccine; 2007 Jan; 25(3):526-34. PubMed ID: 16973247
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunomodulation of Japanese encephalitis vaccine through CpG oligodeoxynucleotides in mice.
    Sidhapuriwala JN; Sivalingam SP; Lu J; Moochhala SM
    Scand J Immunol; 2006 Oct; 64(4):370-5. PubMed ID: 16970676
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vaccination with Newcastle disease vaccine and CpG oligodeoxynucleotides induces specific immunity and protection against Newcastle disease virus in SPF chicken.
    Linghua Z; Xingshan T; Fengzhen Z
    Vet Immunol Immunopathol; 2007 Feb; 115(3-4):216-22. PubMed ID: 17157392
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD8+ T-cell-mediated cross-clade protection in the genital tract following intranasal immunization with inactivated human immunodeficiency virus antigen plus CpG oligodeoxynucleotides.
    Jiang JQ; Patrick A; Moss RB; Rosenthal KL
    J Virol; 2005 Jan; 79(1):393-400. PubMed ID: 15596832
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Induction of systemic and mucosal immune responses by intranasal administration of alginate microspheres encapsulated with tetanus toxoid and CpG-ODN.
    Tafaghodi M; Sajadi Tabassi SA; Jaafari MR
    Int J Pharm; 2006 Aug; 319(1-2):37-43. PubMed ID: 16701972
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adjuvant effects of bacillus Calmette-Guerin DNA or CpG-oligonucleotide in the immune response to Taenia solium cysticercosis vaccine in porcine.
    Guo YJ; Wu D; Wang KY; Sun SH
    Scand J Immunol; 2007 Dec; 66(6):619-27. PubMed ID: 18021362
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune stimulation in the silkworm, Bombyx mori L., by CpG oligodeoxynucleotides.
    Kim I; Kim SH; Lee YS; Yun EK; Lee HS; Kim JW; Ryu KS; Kang PD; Lee IH
    Arch Insect Biochem Physiol; 2004 Jan; 55(1):43-8. PubMed ID: 14691962
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.